371 related articles for article (PubMed ID: 29155868)
1. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
Chen YM; Chen HH; Huang WN; Liao TL; Chen JP; Chao WC; Lin CT; Hung WT; Hsieh CW; Hsieh TY; Chen YH; Chen DY
PLoS One; 2017; 12(11):e0188454. PubMed ID: 29155868
[TBL] [Abstract][Full Text] [Related]
2. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis.
Kume K; Amano K; Yamada S; Kanazawa T; Ohta H; Hatta K; Amano K; Kuwaba N
Rheumatology (Oxford); 2014 May; 53(5):900-3. PubMed ID: 24441151
[TBL] [Abstract][Full Text] [Related]
3. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis.
Briot K; Rouanet S; Schaeverbeke T; Etchepare F; Gaudin P; Perdriger A; Vray M; Steinberg G; Roux C
Joint Bone Spine; 2015 Mar; 82(2):109-15. PubMed ID: 25557658
[TBL] [Abstract][Full Text] [Related]
4. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P; Thompson E; Woodworth T; Smolen JS
Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
Wijbrandts CA; Klaasen R; Dijkgraaf MG; Gerlag DM; van Eck-Smit BL; Tak PP
Ann Rheum Dis; 2009 Mar; 68(3):373-6. PubMed ID: 18408246
[TBL] [Abstract][Full Text] [Related]
6. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
[TBL] [Abstract][Full Text] [Related]
7. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
Buckley LM; Leib ES; Cartularo KS; Vacek PM; Cooper SM
J Rheumatol; 1997 Aug; 24(8):1489-94. PubMed ID: 9263140
[TBL] [Abstract][Full Text] [Related]
8. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
[TBL] [Abstract][Full Text] [Related]
9. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Lange U; Teichmann J; Müller-Ladner U; Strunk J
Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
[TBL] [Abstract][Full Text] [Related]
10. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study.
Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Koike T
Rheumatol Int; 2018 May; 38(5):777-784. PubMed ID: 29294175
[TBL] [Abstract][Full Text] [Related]
11. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
[TBL] [Abstract][Full Text] [Related]
12. Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients.
Orsolini G; Caimmi C; Viapiana O; Idolazzi L; Fracassi E; Gatti D; Adami G; Rossini M
Calcif Tissue Int; 2017 Jul; 101(1):17-23. PubMed ID: 28246933
[TBL] [Abstract][Full Text] [Related]
13. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML;
Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
15. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
16. Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study.
Wheater G; Elshahaly M; Naraghi K; Tuck SP; Datta HK; van Laar JM
PLoS One; 2018; 13(8):e0201527. PubMed ID: 30080871
[TBL] [Abstract][Full Text] [Related]
17. An association between abnormal bone turnover, systemic inflammation, and osteoporosis in patients with chronic pancreatitis: a case-matched study.
Duggan SN; Purcell C; Kilbane M; O'Keane M; McKenna M; Gaffney P; Ridgway PF; Boran G; Conlon KC
Am J Gastroenterol; 2015 Feb; 110(2):336-45. PubMed ID: 25623657
[TBL] [Abstract][Full Text] [Related]
18. Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease.
Guo W; Li F; Zhu C; Wang B; Wang K; Dai C; Jia H; Wei H; He Q; Cui J; Yuan M; Tang S; Liu W; Zhu T; Gao Z; Zheng F; Ma Z; Qu H; Zhu M
J Int Med Res; 2018 Jan; 46(1):492-503. PubMed ID: 28851260
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Low-Dose Disease-modifying Anti-rheumatics Drugs (DMARDs) on Bone Mineral Density of Premenopausal Women in Early Rheumatoid Arthritis.
Rexhepi S; Rexhepi M; Sahatçiu-Meka V; Mahmutaj V; Boshnjaku S
Med Arch; 2016 Apr; 70(2):101-3. PubMed ID: 27147781
[TBL] [Abstract][Full Text] [Related]
20. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
